[go: up one dir, main page]

MX2023005865A - Derivados de dihidrofuropiridina como inhibidores de rho-cinasa. - Google Patents

Derivados de dihidrofuropiridina como inhibidores de rho-cinasa.

Info

Publication number
MX2023005865A
MX2023005865A MX2023005865A MX2023005865A MX2023005865A MX 2023005865 A MX2023005865 A MX 2023005865A MX 2023005865 A MX2023005865 A MX 2023005865A MX 2023005865 A MX2023005865 A MX 2023005865A MX 2023005865 A MX2023005865 A MX 2023005865A
Authority
MX
Mexico
Prior art keywords
dihydrofuropyridine
derivatives
compounds
rho
kinase inhibitors
Prior art date
Application number
MX2023005865A
Other languages
English (en)
Inventor
Fabio Rancati
Anna Maria Capelli
Alessandro Accetta
Christine Edwards
Arnaud Jean Francois Auguste Cheguillaume
Daniele Pala
Adele Elisa Pasqua
Prashant Bhimrao Kapadnis
Original Assignee
Chiesi Farm Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chiesi Farm Spa filed Critical Chiesi Farm Spa
Publication of MX2023005865A publication Critical patent/MX2023005865A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pulmonology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La invención se refiere a compuestos de la fórmula (I) que inhiben la Rho cinasa que son derivados de la dihidrofuropiridina, métodos para preparar estos compuestos, composiciones farmacéuticas que los contienen y uso terapéutico de los mismos. Particularmente, los compuestos de la invención pueden ser útiles en el tratamiento de muchos trastornos asociados con mecanismos de enzimas ROCK, tal como enfermedades pulmonares que incluyen asma, enfermedad pulmonar obstructiva crónica (COPD), fibrosis pulmonar idiopática (IPF) e hipertensión arterial pulmonar (PAH).
MX2023005865A 2020-12-15 2021-12-13 Derivados de dihidrofuropiridina como inhibidores de rho-cinasa. MX2023005865A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP20214148 2020-12-15
PCT/EP2021/085378 WO2022128851A1 (en) 2020-12-15 2021-12-13 Dihydrofuropyridine derivatives as rho- kinase inhibitors

Publications (1)

Publication Number Publication Date
MX2023005865A true MX2023005865A (es) 2023-06-05

Family

ID=73854548

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023005865A MX2023005865A (es) 2020-12-15 2021-12-13 Derivados de dihidrofuropiridina como inhibidores de rho-cinasa.

Country Status (10)

Country Link
US (1) US12534474B2 (es)
EP (1) EP4263546B1 (es)
JP (1) JP2023552901A (es)
KR (1) KR20230121811A (es)
CN (1) CN116568303A (es)
AU (1) AU2021403631A1 (es)
CA (1) CA3202126A1 (es)
ES (1) ES3041794T3 (es)
MX (1) MX2023005865A (es)
WO (1) WO2022128851A1 (es)

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1562935B1 (de) 2002-10-28 2006-09-06 Bayer HealthCare AG Heteroaryloxy-substituierte phenylaminopyrimidine als rho-kinaseinhibitoren
JP2008503492A (ja) 2004-06-17 2008-02-07 スミスクライン・ビーチャム・コーポレイション Ｒｈｏ−キナーゼの新規阻害剤
US20110150833A1 (en) 2007-12-21 2011-06-23 The Scripps Research Institute Benzopyrans and analogs as rho kinase inhibitors
US20110166161A1 (en) 2008-09-18 2011-07-07 Astellas Pharma Inc. Heterocyclic carboxamide compounds
PH12013500084A1 (en) 2010-07-14 2015-09-11 Novartis Ag Ip receptor agonist heterocyclic compounds
EP2951172B8 (en) 2013-01-29 2017-08-02 Redx Pharma Plc Pyridine derivatives as soft rock inhibitors
AR110401A1 (es) 2016-12-21 2019-03-27 Chiesi Farm Spa Derivados dihidropirimidina bicíclica-carboxamida como inhibidores de rho-quinasa
PE20191744A1 (es) 2017-01-30 2019-12-12 Chiesi Farm Spa Derivados de tirosinamida como inhibidores de rho-quinasa
MA50074A (fr) 2017-09-07 2021-04-28 Chiesi Farm Spa Dérivés d'analogues de tyrosine en tant qu'inhibiteurs de rho-kinase
US11725007B2 (en) 2017-12-18 2023-08-15 Chiesi Farmaceutici S.P.A. Meta tyrosine derivatives as rho-kinase inhibitors
MA51284A (fr) 2017-12-18 2021-05-26 Chiesi Farm Spa Dérivés d'oxadiazole en tant qu'inhibiteurs de kinase rho
EP3728248B1 (en) 2017-12-18 2022-02-02 Chiesi Farmaceutici S.p.A. Azaindole derivatives as rho-kinase inhibitors
AR114926A1 (es) 2018-06-13 2020-10-28 Chiesi Farm Spa Derivados de azaindol como inhibidores de rho-quinasa
TW202019923A (zh) 2018-07-16 2020-06-01 義大利商吉斯藥品公司 作為Ｒｈｏ－激酶抑制劑之酪胺酸醯胺衍生物

Also Published As

Publication number Publication date
EP4263546B1 (en) 2025-07-02
KR20230121811A (ko) 2023-08-21
WO2022128851A1 (en) 2022-06-23
ES3041794T3 (en) 2025-11-14
EP4263546A1 (en) 2023-10-25
US12534474B2 (en) 2026-01-27
AU2021403631A1 (en) 2023-07-27
JP2023552901A (ja) 2023-12-19
CN116568303A (zh) 2023-08-08
US20240092792A1 (en) 2024-03-21
CA3202126A1 (en) 2022-06-23
EP4263546C0 (en) 2025-07-02

Similar Documents

Publication Publication Date Title
MX393050B (es) Derivados de amida de tirosina como inhibidores de rho-cinasa.
MX2021014113A (es) Derivados de aminoquinazolina como inhibidores del purinoreceptor 3 de p2x (p2x3).
MX2019005526A (es) Derivados biciclicos de dihidropirimidina-carboxamida como inhibidores de rho-cinasa.
ECSP088335A (es) Compuestos de pirimidina amida como inhibidores de pgds
ECSP14013173A (es) 3,5-diamino-6-cloro-n-(n-(4-(4-(2-(hexil(2,3,4,5,6-pentahidroxihexil)amino)etoxi)fenil)butil) carbamimidoil)pirazina-2-carboxamida
EA202092678A1 (ru) 1,3-тиазол-2-ил-замещенные бензамиды для лечения заболеваний, ассоциированных с сенситизацией нервных волокон
MX2021000270A (es) Derivados de la tirosina amida como inhibidores de la rho- cinasa.
BR112012007635A2 (pt) derivados de feniloxadiazol como inibidores de pgds
NO20070076L (no) Nye indazolkarboksamider og deres anvendelse
MX2021014116A (es) Derivados de piridopirimidinas como inhibidores del purinoreceptor 3 de p2x (p2x3).
MX2023005865A (es) Derivados de dihidrofuropiridina como inhibidores de rho-cinasa.
MX2022006735A (es) Análogos de nucleósidos sustituidos como inhibidores de la prmt5.
MX2023005801A (es) Derivados de ftalazina como inhibidores de purinoceptor 3 de p2x (p2x3).
CO2023009444A2 (es) Derivados de dihidrofuropiridina como inhibidores de la rho-cinasa
MX2023005805A (es) Derivados de 4-aminas de (aza)quinolina como inhibidores del purinorreceptor 3 p2x (p2x3).
MX2023005803A (es) Derivados de amino-quinazolina como inhibidores del purinorreceptor 3 p2x (p2x3).
MX2023005866A (es) Derivados de dihidrofuropiridina como inhibidores de rho-cinasa.
MX2021015553A (es) Inhibidores de arginasa novedosos.
WO2015028957A3 (en) Compounds and methods for the treatment of respiratory diseases
EA202193300A1 (ru) Производные аминохиназолина в качестве p2x3 ингибиторов
CO2025004441A2 (es) Derivados heterocíclicos como inhibidores de cinasa janus
MX2022004809A (es) Composiciones para prevenir o tratar enfermedad pulmonar obstructiva cronica (epoc).
BRPI0608446A2 (pt) formas cristalinas de um composto de bifenila
WO2015008205A3 (en) Compositions and methods for the treatment of respiratory diseases